• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases.受体相互作用蛋白激酶1（RIPK1）抑制剂作为多种炎症性和神经退行性疾病的潜在治疗方法。
ACS Med Chem Lett. 2025 Jan 27;16(2):204-206. doi: 10.1021/acsmedchemlett.5c00026. eCollection 2025 Feb 13.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
4
From RIPK1 to Necroptosis: Pathogenic Mechanisms in Neurodegenerative Diseases.从受体相互作用蛋白激酶1到坏死性凋亡：神经退行性疾病中的致病机制
Neurochem Res. 2025 Jun 10;50(3):194. doi: 10.1007/s11064-025-04448-1.
5
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
6
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.运动神经元病/肌萎缩侧索硬化症患者流涎（唾液过多）的治疗。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3.
7
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.肌萎缩侧索硬化症/运动神经元病的对症治疗
Cochrane Database Syst Rev. 2017 Jan 10;1(1):CD011776. doi: 10.1002/14651858.CD011776.pub2.
10
Inhibition of the Binding of Interleukin 17A with Interleukin 17A Receptor as a Treatment for Immune System and Inflammation Disorders, Cancer, and Neurodegenerative Diseases.抑制白细胞介素17A与白细胞介素17A受体的结合作为免疫系统和炎症性疾病、癌症及神经退行性疾病的一种治疗方法。
ACS Med Chem Lett. 2024 Nov 19;15(12):2088-2090. doi: 10.1021/acsmedchemlett.4c00532. eCollection 2024 Dec 12.

本文引用的文献

1
Targeting necroptosis: a promising avenue for respiratory disease treatment.靶向细胞坏死性凋亡：呼吸系统疾病治疗的新途径。
Cell Commun Signal. 2024 Aug 28;22(1):418. doi: 10.1186/s12964-024-01804-6.
2
RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development.RIPK1 抑制剂：在药物研发中解锁细胞坏死性凋亡潜能的关键。
Eur J Med Chem. 2024 Feb 5;265:116123. doi: 10.1016/j.ejmech.2024.116123. Epub 2024 Jan 3.
3
A guide to cell death pathways.细胞死亡途径指南。
Nat Rev Mol Cell Biol. 2024 May;25(5):379-395. doi: 10.1038/s41580-023-00689-6. Epub 2023 Dec 18.
4
Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease.受体相互作用蛋白激酶 1（RIPK1）的分子和功能特征及其在阿尔茨海默病中的治疗潜力。
Drug Discov Today. 2023 Dec;28(12):103750. doi: 10.1016/j.drudis.2023.103750. Epub 2023 Aug 24.
5
Targeting RIPK1 kinase for modulating inflammation in human diseases.靶向 RIPK1 激酶调节人类疾病中的炎症反应。
Front Immunol. 2023 Mar 8;14:1159743. doi: 10.3389/fimmu.2023.1159743. eCollection 2023.

受体相互作用蛋白激酶1（RIPK1）抑制剂作为多种炎症性和神经退行性疾病的潜在治疗方法。

Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases.

作者信息

Abdel-Magid Ahmed F

机构信息

PI Health Sciences, 100 Jade Park, Chelsea, Alabama 35043, United States.

出版信息

ACS Med Chem Lett. 2025 Jan 27;16(2):204-206. doi: 10.1021/acsmedchemlett.5c00026. eCollection 2025 Feb 13.

DOI:10.1021/acsmedchemlett.5c00026
PMID:39967643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11831378/
Abstract

The invention in this patent application relates to 2-amino-[1,2,4]triazolo[1,5-]pyridin derivatives represented generally herein as formula 1. These compounds have activities as receptor-interacting protein kinase 1 (RIPK1) inhibitors and may potentially provide treatment and/or prophylaxis of inflammatory and neurodegenerative diseases associated with aberrant RIPK1 activity such as ulcerative colitis, Crohn's disease, psoriasis, NASH, heart failure, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.

摘要

本专利申请中的发明涉及本文一般表示为式1的2-氨基-[1,2,4]三唑并[1,5-a]吡啶衍生物。这些化合物具有作为受体相互作用蛋白激酶1（RIPK1）抑制剂的活性，并可能潜在地提供与异常RIPK1活性相关的炎性和神经退行性疾病的治疗和/或预防，例如溃疡性结肠炎、克罗恩病、银屑病、非酒精性脂肪性肝炎、心力衰竭、多发性硬化症、肌萎缩侧索硬化症（ALS）和阿尔茨海默病。